, Executive Vice President & Chief Technology Officer
Dushyant B. Varshney, Ph.D., is the Executive Vice President & Chief Technology Officer. He is responsible for Global CMC, Technical Operations & Quality, including technology innovation, product development, manufacturing, technology transfer and commercialization of Drug Substance and Finished Drug Products.
Dr. Varshney has over 25 years of experience at global bio-pharma organizations, leading the entire product life-cycle of diverse biotech modalities including mRNA therapeutics, gene & cell-based therapy, biologics and vaccines. He has made significant contributions towards 30+ launches, 75+ INDs, BLA, PAS submissions, and ensured supply of more than 7B+ doses, $20B+ revenues at companies including Gilead, Pfizer, Novartis and Sanofi.
Before joining Arcturus, Dr. Varshney was the Global Head of Manufacturing, Science & Technology at Gilead-Kite, where he built a strong organization & rapid commercialization strategy for successful technology transfers, launch & patient access of Yescarta®, Tecartus®, viral vectors and clinical products. Prior to that, he served as the Vice President, Global Head of Technical Services, Operations & Supply at Jubilant, and as the Head of Manufacturing, Science & Technology at Pfizer, led America, Europe & Asia Pacific teams. At Novartis, contributed to commercial technology transfer, qualification, manufacturing of Flucelvax® (first US cell-based influenza vaccine) Trivalent & Quadrivalent, Pre-Pandemic Vaccine stockpiles (bird & swine-flu, H5N1, H3N2, H7N9), and pandemic response strategies.
Dushyant received his Ph.D. in Chemistry from University of Iowa, M. Pharm from Institute of Chemical Technology, Mumbai, and B. Pharm from University of Pune in India. He is a Stephen Covey Leadership Coach, Master Black-Belt in Operational Excellence, made 120+ conference presentations, published 40+ articles, chapters and edited the book “Lyophilized Biologics & Vaccines” published by Springer.